|
|
|
European Biopharmaceutical Review
|
The discovery of penicillin by Alexander Fleming in 1928 revolutionised medicine. This antibiotic soon became one of the most widely used in treating common bacterial infections, as well as pneumonia, tuberculosis, syphilis, and more (1). However, the Nobel Prize winner also predicted how an irresponsible use of penicillin could lead to the development of resistant bacteria, resulting in losing the antibiotic efficacy and death caused by a lack of alternative treatments. His concern has become a real-life scenario, affecting the medical sector and animal husbandry on a global scale.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Watson-Marlow Fluid Technology Solutions and the National Institute for Bioprocessing Research and Training Partner for Biopharma Training Programme
Falmouth, UK, 3rd May 2022 / Sciad Newswire / Watson-Marlow Fluid
Technology Solutions (WMFTS) today announces it has partnered with the
National Institute of Bioprocessing Research and Training (NIBRT) to
develop and deliver a combined in-person and online global biopharma
training programme for employees.
More info >> |
|
 |
White Papers |
 |
|
PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance
Phlexglobal Ltd
Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >> |
|
|
